The condition can affect several organs including the heart, lungs and kidneys. If it is not diagnosed or treated on time, it could threaten the patient’s existence. It is yet to be ascertained why children contract this complication
Respiratory Syncytial Virus (RSV) is estimated to affect 64 million people and claims around 160 000 lives around the world every year and there is still no effective vaccine.
Infants are most vulnerable to respiratory syncytial virus and there is no effective treatment or vaccine. Tiyese Jeranji asks what we know about the virus in South Africa.
New nirsevimab data analyses reinforce efficacy against RSVA prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the firs.